|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��������,������ |
|
�����������岡 |
|
���� |
| ��������������� | |
|
Ԭ��ϼ |
|
���� |
| PubMed | |
|
Article by YUAN Yan-xia |
|
Article by LIN Lin |
����ע���������������������Դ��岡����״
Ԭ��ϼ, ����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
����ע����������Ϊһ�����ߵ��ڼ������ƶ�����������Լ����������������岡����Ƥ������ʹ�þ���ע������������Ч�ļ���֮һ���÷���������Ӧ�����Ҵ����������,ΪһЩ�������ƽ��ɻ���Ч�Ļ����ṩ�˰�ȫ��Ч������ѡ����ȷ�е����û�����δ��ȫ����,���������о���ʾ�����뿹�����Ϳ��塢�к�Fc���塢����ϸ���������硢Ӱ�췢���е�ϸ���������̵��йء�
Current Situation of the Application of Intravenous Immunoglobulin in Autoimmune Blistering Diseases
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Intravenous immunoglobulin has been shown to be effective in the treatment of many immune-mediated diseases as an immunomodulatory agent. Autoimmune mucocutaneous blistering diseases are among those skin diseases which well respond to intravenous immunoglobulin with fewer adverse effects. Intravenous immunoglobulin may be an effective alternative therapy for patients who are contraindicate to or fail to conventional treatments. Rencently, numerous mechanisms have been proposes to explain the mode of action of intravenous immunoglobulin, including antiidiotypic antibodies, regulation of functions of Fc receptors, interference with the cytokine network, and anti-apoptotic effects, etc.
[2] Jolles S.A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders.Clin Exp Dermatol,2001,26:127-131.
[3] Ahmed AR.Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.J Am Acad Dermatol,2001,45:825-835.
[4] Ahmed AR,Colon JE.Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid:effects on disease progression in patients nonresponsive to dapsone therapy.Arch Dermatol,2001,137:1181-1189.
[5] Sami N,Bhol KC,Ahmed AR.Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy.Long-term follow-up:influence of treatment on antibody titres to human alpha6integrin.Clin Exp Immunol,2002,129:533-540.
[6] Ahmed AR.Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.J Am Acad Dermatol,2001,45:679-690.
[7] Sami N,Bhol KC,Ahmed RA.Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.Eur J Dermatol,2003,13:377-381.
[8] Sami N,Ali S,Bhol KC,et al.Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Agl and BP Ag2 in patients with bullous pemphigoid.J Eur Acad Dermatol Venereol,2003,17:641-645.
[9] Ahmed AR,Dahl MV.Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases.Arch Dermatol,2003,139:1051.
[10] Mydlarski PR,Mittmann N,Shear NH.Intravenous immunoglobulin:use in dermatology.Skin Therapy Lett,2004,9:1-6.
[11] Sheehan DJ,Lesher JL Jr.Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment ofpemphigus vulgaris.Cutis,2004,73:403-406.
[12] Bystryn JC,Rudolph JL.IVI g TREATMENT OF PEMPHIGUS:how it works and how to use it.J Invest Dermatol,2005,125:1093.
[13] Li N,Zhao M,Hilario-Vargas J,et al.Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.JClin Invest,2005,115:3440-3450.
[14] Mimouni D,Blank M,Ashkenazi L,et al.Protective effect of intravenous immunoglobulin (MG) in an experimental model of pemphigus vulgaris.Clin Exp Immunol,2005,142:426-432.
[15] Bhol KC,Desai A,Kumari S,et al.Pemphigus vulgaris:the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production.Clin Immunol,2001,100:172-180.
[16] Wang X,Bregegere F,Frusic-Zlotkin M,et al.Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins.Apoptosis,2004,9:131-143.
[17] Arredondo J,Chernyavsky AI,Karaouni A,et al.Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus.Am J Pathol,2005,167:1531-1544.